Twice-daily and three-times-daily dosing of a repaglinide/metformin fixed-dose combination tablet provide similar glycaemic control

Diabetes, Obesity and Metabolism

Volumn 11, Issue 10, 2009, Pages 947-952

  Raskin, P ^a   Lewin, A ^b   Reinhardt, R ^c   Lyness, W ^c  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b NATIONAL RESEARCH INSTITUTE   (United States)

^c NOVO NORDISK INC   (United States)

Author keywords

Antidiabetic drugs; Clinical trials; Diabetes; Glycaemic control; Repaglinide

Indexed keywords

ANTIDIABETIC AGENT; HEMOGLOBIN A1C; METFORMIN PLUS REPAGLINIDE; METFORMIN PLUS ROSIGLITAZONE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CHOLELITHIASIS; CLINICAL TRIAL; DEPRESSION; DIABETIC NEUROPATHY; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; HYPONATREMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEPHROLITHIASIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; PATIENT SATISFACTION; PRESYNCOPE; SIDE EFFECT; TABLET; THORAX PAIN; TRAFFIC ACCIDENT; TRANSIENT ISCHEMIC ATTACK; UPPER RESPIRATORY TRACT INFECTION; WEIGHT CHANGE;

ADULT; BLOOD GLUCOSE; CARBAMATES; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; PATIENT SATISFACTION; PIPERIDINES; TABLETS; YOUNG ADULT;

EID: 69249204300     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2009.01069.x     Document Type: Article

References (11)

1. Moses R, Slobodniuk R, Boyages S. Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 1999, 22:119-124.
2. Raskin P, Klaff L, McGill J. Efficacy and safety of combination therapy: repaglinide plus metformin versus nateglinide plus metformin. Diabetes Care 2003, 26:2063-2068.
3. Reboussin DM, Goff DC, Lipkin EW. The combination oral and nutritional treatment of late-onset diabetes mellitus (CONTROL DM) trial results. Diabet Med 2004, 21:1082-1089.
4. Rudovich NN, Leyck Dieken MG, Rochlitz H, Pfeiffer AF. Enhancement of early- and late-phase insulin secretion and insulin sensitivity by the combination of repaglinide and metformin in type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 2004, 112:395-400.
5. Shapiro MS, Abrams Z, Lieberman N. Clinical experience with repaglinide in patients with non-insulin-dependent diabetes mellitus. Isr Med Assoc J 2005, 7:75-77.
6. Soegondo S, Subekti I, Luthariana L. The efficacy of repaglinide monotherapy and in combination with metformin in Indonesian type 2 diabetes mellitus patients. Acta Med Indones 2004, 36:142-147.
7. http://www.prandin.com/docs/prandin_insert.pdf, Available from URL, Accessed 3 March 2009
8. Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007, 120:713-719.
9. Melikian C, White TJ, Vanderplas A, Dezii CM, Chang E. Adherence to oral antidiabetic therapy in a managed care organization: a comparison of monotherapy, combination therapy, and fixed-dose combination therapy. Clin Ther 2002, 24:460-467.
10. Raskin R, Lewin A, Reinhardt R, Lyness W. Twice-daily dosing of a repaglinide/ metformin fixed-dose combination tablet provides glycaemic control comparable to rosiglitazone/ metformin tablet. Diabetes, Obesity and Metabolism. In press
11. Marbury T, Huang WC, Strange P, Lebovitz H. Repaglinide versus glyburide: a one-year comparison trial. Diabetes Res Clin Pract 1999, 43:155-166.